Says “exciting time” for biosimilars. Sees ~$700M of net savings by 2027 with two thirds expected to be realized by 2026. Expects portfolio to “overdeliver” for full year. Says U.S. tariffs “absorbed” in FY25 non-GAAP outlook. Comments taken from Q2 earnings conference call.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA: